Inactive Instrument

Press Releases Qiagen Nasdaq

Equities

NL0012169213

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

Qiagen N : 2023 Annual Report 2023 IFRS Annual Report	Apr. 25	PU
QIAGEN expands tuberculosis portfolio with new NGS Panel to support real-time surveillance and combat antimicrobial resistance	Apr. 24	AQ
QIAGEN N.V. to release results for Q1 2024 and hold webcast	Apr. 09	AQ
Qiagen N : launches new solution for screening of sexual assault forensic casework samples	Apr. 04	PU
QIAGEN strengthens its portfolio for cancer research, showcasing latest product launches at AACR Annual Meeting 2024	Apr. 03	AQ
QIAGEN introduces QIAstat-Dx Analyzer 2.0 with remote test results access, enhancing collaboration across healthcare system	Mar. 25	AQ
QIAGEN partners with International Panel Physicians Association to increase awareness of tuberculosis screening requirements	Mar. 18	AQ
Qiagen N : Virtual Exane Conference Investor Introduction	Mar. 11	PU
Qiagen N : TD Cowen Healthcare Conference March 5-6 Investor Introduction	Mar. 11	PU
QIAGEN announces Form 20-F annual report filing for 2023 results	Mar. 11	AQ
For the UK: QIAGEN Ltd statement about the Modern Slavery Act 2015 for 2024	Mar. 06	PU
QIAGEN launches AI-derived biomedical knowledge base to accelerate data-driven drug discovery	Feb. 27	AQ
QIAGEN earns ACT Label for new eco-friendlier QIAwave products and achieves first My Green Lab Platinum certification	Feb. 27	AQ
Qiagen N : Share buyback program initiated in 2024 2024 Federal-8937 Report of Organizational Actions Affecting Basis of Securities (SSBB)_RS signed	Feb. 20	PU
QIAGEN earns ACT Label for new eco-friendlier QIAwave products and achieves first My Green Lab Platinum certification	Feb. 15	AQ
Qiagen: Q4 Earnings Snapshot	Feb. 06	AQ
QIAGEN exceeds outlook for Q4 2023, led by 8% CER sales growth in non-COVID products and improved operational profitability	Feb. 06	AQ
QIAGEN announces partnership with Penn State University to advance microbiome sciences	Jan. 25	AQ
QIAGEN announces details for completion of synthetic share repurchase of up to approximately $300 million	Jan. 18	AQ
QIAGEN N.V. to release results for Q4 2023 and hold webcast	Jan. 11	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

QIAGEN : In line Q4; routine business prospects remain intact

February 07, 2024 at 10:30 am EST